Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr Eskander on Pembrolizumab Plus Paclitaxel and Carboplatin in Endometrial Cancer

March 28th 2023

Ramez N. Eskander, MD, discusses findings from the phase 3 NRG GY018 trial of pembrolizumab plus chemotherapy in patients with endometrial cancer.

Dostarlimab Plus Chemotherapy Elicits PFS Benefit in Recurrent Endometrial Cancer

March 28th 2023

Dostarlimab plus standard-of-care chemotherapy generated a significant improvement in progression-free survival vs chemotherapy alone for patients with recurrent endometrial cancer, including those with mismatch repair–deficient, microsatellite instability–high tumors.

Dr Mirza on Dostarlimab Plus Chemotherapy in Endometrial Cancer

March 28th 2023

Mansoor Raza Mirza, MD, discusses findings from the phase 3 RUBY trial in patients with endometrial cancer.

Dr Polan on Perioperative Outcomes With Supracervical or Total Hysterectomy Plus Colorectal Resection

March 27th 2023

Rosa M. Polan, MD, discusses key data from a comparison of perioperative outcomes with supracervical and total hysterectomy performed with concurrent colorectal resection in women.

Lenvatinib Plus Pembrolizumab Produces Deep, Sustained Responses in Advanced Endometrial Cancer

March 27th 2023

The combination of lenvatinib plus pembrolizumab produced deep, durable tumor responses in both all-comer and mismatch repair–proficient (pMRR) populations of patients with advanced endometrial cancer, according to data from the phase 3 Study 309/KEYNOTE-775 trial.

Durvalumab Plus Tremelimumab and Hypofractionated Radiotherapy Shows Early Promise in Gynecologic Cancers

March 27th 2023

The combination of durvalumab, tremelimumab, and hypofractionated radiotherapy demonstrated early tolerability in patients with gynecologic malignancies and elicited objective responses in those with PD-L1–high tumors.

Olaparib Plus Selumetinib Produces Clinical Benefit in RAS-Mutated Ovarian and Endometrial Cancer

March 27th 2023

The recommended phase 2 dose of olaparib plus selumetinib generated a clinical benefit in patients with endometrial or ovarian cancer harboring RAS mutations, according to findings from the dose-expansion portion of the phase 1b SOLAR trial.

Similar Total Scores Are Observed With GCLQ and LELSQ in Assessing Patients With Endometrial Cancer for Lymphedema

March 26th 2023

The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed moderate to substantial agreement across different cutoff points.

Dr. Roque on the Importance of Biomarker Testing in Advanced Endometrial Cancer

March 23rd 2023

Dario R. Roque, MD, discusses how biomarker testing can lead to more accurate and effective treatment selection in advanced endometrial cancer.

VTP-200 Elicits Immunogenic Responses, Tolerability in HPV+ Cervical Lesions

March 20th 2023

VTP-200 generated immunogenic responses and tolerability in patients with human papillomavirus–positive cervical lesions.

Dostarlimab Fills Unmet Need for Patients with dMMR Advanced Endometrial Cancer

March 20th 2023

Lucy Gilbert, MD, MSc, discusses the favorable safety profile of dostarlimab as well as how it compares with the current standard of care in mismatch repair deficient advanced endometrial cancer.

Coleman Illuminates Opportunities in Gynecologic Malignancies

March 17th 2023

Robert L. Coleman, MD, FACOG, FACS, the 2020 Giants of Cancer Care® award winner in gynecologic malignancies, notes that despite the great progress in the past decade, more work is needed to personalize and refine approaches to care.

Minimally Invasive Surgery, PARP Inhibitors, ADCs Propel Treatment Advances Across Gynecologic Oncology

March 9th 2023

Jubilee Brown, MD, discusses future considerations for using minimally invasive surgery and PARP inhibitors in ovarian cancer, how immunotherapies have fulfilled an unmet need in cervical cancer, and the importance of leveraging molecular profiling to determine personalized therapeutic strategies in endometrial cancer.

Lenvatinib Plus Pembrolizumab Generates Durable Responses in Advanced Endometrial Carcinoma

February 26th 2023

Lenvatinib in combination with pembrolizumab led to deep and durable tumor responses in patients with previously treated advanced endometrial carcinoma.

Dr. Barber on the Role of Molecular Profiling for Treatment Considerations in Endometrial Cancer

February 23rd 2023

Emma L. Barber, MD, discusses the role of molecular profiling for treatment considerations in patients with endometrial cancer.

Long-term Data for Niraparib Support Continued Use of PARP Inhibitors in HRD+ Ovarian Cancer

February 14th 2023

Dario R. Roque, MD, discusses incorporating PARP inhibitors into practice for patients with homologous recombination deficient ovarian cancer, the role of PARP inhibitors for patients with homologous recombination–proficient ovarian cancer and the expanding investigation of mirvetuximab soravtansine in ovarian cancer.

FDA Grants Regular Approval to Dostarlimab for dMMR Endometrial Cancer

February 9th 2023

The FDA has granted a regular approval to dostarlimab-gxly (Jemperli) for adult patients with mismatch repair–deficient, recurrent or advanced endometrial cancer that has progressed on or after a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.

Biomarkers Clarify Treatment Decisions and Sequencing in Endometrial Cancer

February 9th 2023

Emma L. Barber, MD, emphasized the importance of the ongoing phase 3 PORTEC-4a trial, which is investigating the role of molecular risk profiles in determining whether patients with endometrial cancer should receive no adjuvant therapy, vaginal brachytherapy, or external beam radiotherapy.

ONA-XR/Anastrozole Combo Delivers Promising Early Results in HR+ Metastatic Endometrial Cancer

February 8th 2023

Oral progesterone receptor antagonist onapristone extended release in combination with anastrozole induced a confirmed partial response in 2 patients with hormone receptor–positive metastatic endometrial cancer.

Dr. Herzog on the FDA Approval of Mirvetuximab Soravtansine in FRα–positive Gynecologic Cancers

February 6th 2023

Thomas Herzog, MD, discusses how the recent FDA approval of the novel antibody-drug conjugate mirvetuximab soravtansine-gynx ameliorates unmet need in platinum-resistant, folate receptor alpha–positive gynecological cancers.